116 related articles for article (PubMed ID: 8822843)
1. Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo.
Hong YL; Hossler P; Bartlett M; Queener S; Smith J; Meshnick S
J Eukaryot Microbiol; 1996; 43(5):40S. PubMed ID: 8822843
[No Abstract] [Full Text] [Related]
2. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.
Hong YL; Hossler PA; Calhoun DH; Meshnick SR
Antimicrob Agents Chemother; 1995 Aug; 39(8):1756-63. PubMed ID: 7486915
[TBL] [Abstract][Full Text] [Related]
3. Sulfa resistance in mouse-derived Pneumocystis carinii.
Lane B; Hossler P; Bartlett M; Queener S; O'Reilly T; Smith J; Meshnick S
J Eukaryot Microbiol; 1996; 43(5):39S. PubMed ID: 8822842
[No Abstract] [Full Text] [Related]
4. Quantitative structure-activity relationship studies of a series of sulfa drugs as inhibitors of Pneumocystis carinii dihydropteroate synthetase.
Johnson T; Khan IA; Avery MA; Grant J; Meshnick SR
Antimicrob Agents Chemother; 1998 Jun; 42(6):1454-8. PubMed ID: 9624493
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.
Merali S; Zhang Y; Sloan D; Meshnick S
Antimicrob Agents Chemother; 1990 Jun; 34(6):1075-8. PubMed ID: 2203302
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.
Iliades P; Meshnick SR; Macreadie IG
Antimicrob Agents Chemother; 2005 Feb; 49(2):741-8. PubMed ID: 15673759
[TBL] [Abstract][Full Text] [Related]
7. A need for standardized definitions for clinical studies of Pneumocystis.
Miller RF; Huang L
J Eukaryot Microbiol; 2006; 53 Suppl 1():S87-8. PubMed ID: 17169079
[No Abstract] [Full Text] [Related]
8. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase.
Volpe F; Ballantine SP; Delves CJ
Eur J Biochem; 1993 Sep; 216(2):449-58. PubMed ID: 8397083
[TBL] [Abstract][Full Text] [Related]
9. Sulfa and trimethoprim-like drugs - antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors.
Capasso C; Supuran CT
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):379-87. PubMed ID: 23627736
[TBL] [Abstract][Full Text] [Related]
10. Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.
Chio LC; Bolyard LA; Nasr M; Queener SF
Antimicrob Agents Chemother; 1996 Mar; 40(3):727-33. PubMed ID: 8851601
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jiroveci dihydropteroate synthase polymorphisms confer resistance to sulfadoxine and sulfanilamide in Saccharomyces cerevisiae.
Meneau I; Sanglard D; Bille J; Hauser PM
Antimicrob Agents Chemother; 2004 Jul; 48(7):2610-6. PubMed ID: 15215117
[TBL] [Abstract][Full Text] [Related]
12. Absence of mutations associated with sulfa resistance in Pneumocystis carinii dihydropteroate synthase gene from non-human primates.
Demanche C; Guillot J; Berthelemy M; Petitt T; Roux P; Wakefield AE
Med Mycol; 2002 Jun; 40(3):315-8. PubMed ID: 12146763
[TBL] [Abstract][Full Text] [Related]
13. Effects of sterol inhibitors on the ATP content of Pneumocystis carinii.
Kaneshiro ES; Collins M; Cushion MT
J Eukaryot Microbiol; 1999; 46(5):142S-143S. PubMed ID: 10519292
[No Abstract] [Full Text] [Related]
14. Drug-resistant Pneumocystis carinii.
Meshnick SR
Lancet; 1999 Oct; 354(9187):1318-9. PubMed ID: 10533856
[No Abstract] [Full Text] [Related]
15. Dihydropteroate synthase polymorphisms in Pneumocystis carinii.
Lane BR; Ast JC; Hossler PA; Mindell DP; Bartlett MS; Smith JW; Meshnick SR
J Infect Dis; 1997 Feb; 175(2):482-5. PubMed ID: 9203679
[TBL] [Abstract][Full Text] [Related]
16. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii appears to encode dihydropteroate synthase and hydroxymethyldihydropterin pyrophosphokinase.
Volpe F; Dyer M; Scaife JG; Darby G; Stammers DK; Delves CJ
Gene; 1992 Mar; 112(2):213-8. PubMed ID: 1313386
[TBL] [Abstract][Full Text] [Related]
17. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone).
Voeller D; Kovacs J; Andrawis V; Chu E; Masur H; Allegra C
J Infect Dis; 1994 Feb; 169(2):456-9. PubMed ID: 8106784
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients.
Kazanjian P; Locke AB; Hossler PA; Lane BR; Bartlett MS; Smith JW; Cannon M; Meshnick SR
AIDS; 1998 May; 12(8):873-8. PubMed ID: 9631140
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.
Ma L; Borio L; Masur H; Kovacs JA
J Infect Dis; 1999 Dec; 180(6):1969-78. PubMed ID: 10558954
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of dihydropteroate synthase mutations in Spanish patients with HIV-associated Pneumocystis pneumonia.
Friaza V; Montes-Cano MA; Respaldiza N; Morilla R; Calderón EJ; de la Horra C
Diagn Microbiol Infect Dis; 2009 May; 64(1):104-5; author reply 106-7. PubMed ID: 19232864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
